InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

- Current share price for NOX : $0.059

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$18 Appendix 4G and Corporate Governance Statement 13 Oct 2025 5:12PM $0.105 $0.059 fallen by 43.81%
$18 Audited Financial Statements 29 Sep 2025 9:52AM $0.098 $0.059 fallen by 39.80%
$18 Extension of Convertible Notes and Funding 23 Sep 2025 8:29AM $0.110 $0.059 fallen by 46.36%
$18 HERACLES clinical trial Update 4 8 Sep 2025 9:25AM $0.105 $0.059 fallen by 43.81%
$18 Appendix 4E Preliminary Final Report 29 Aug 2025 8:08AM $0.100 $0.059 fallen by 41%
$18 Appendix 4E Preliminary Final Report 29 Aug 2025 8:08AM $0.100 $0.059 fallen by 41%
$18 Sofra technology platform presentation 28 Aug 2025 8:58AM $0.115 $0.059 fallen by 48.70%
$18 HERACLES clinical trial Update 3 25 Aug 2025 9:30AM $0.115 $0.059 fallen by 48.70%
$18 HERACLES clinical trial Update 2 11 Aug 2025 8:31AM $0.110 $0.059 fallen by 46.36%
$18 US company demonstrates strong Sofra potential 5 Aug 2025 8:28AM $0.115 $0.059 fallen by 48.70%
$18 June 2025 Quarterly Activities Report and Appendix 4C 30 Jul 2025 8:30AM $0.125 $0.059 fallen by 52.80%
$18 HERACLES clinical trial - Update 1 28 Jul 2025 9:39AM $0.075 $0.059 fallen by 21.33%
$18 First SOF-SKN dose in HERACLES clinical trial 16 Jul 2025 8:14AM $0.048 $0.059 risen by 22.92%
$18 Clinical trial recruitment progressing rapidly 25 Jun 2025 10:08AM $0.051 $0.059 risen by 15.69%
$18 Promising Sofra results from overseas company 11 Jun 2025 11:11AM $0.066 $0.059 fallen by 10.61%
$18 Green light for HERACLES clinical trial 29 May 2025 8:37AM $0.066 $0.059 fallen by 10.61%
$18 NYR: Notice of Ceasing to be a Substantial Holder - NOX 21 May 2025 8:21AM $0.068 $0.059 fallen by 13.24%
$18 Notice of Change of Interests of Substantial Holder for NYR 20 May 2025 9:29AM $0.068 $0.059 fallen by 13.24%
$18 NYR: Corporate Update 20 May 2025 9:20AM $0.068 $0.059 fallen by 13.24%
$18 New funds from Nyrada share sales 20 May 2025 8:48AM $0.068 $0.059 fallen by 13.24%
$18 SOF-SKN data presented at rheumatology conference 6 May 2025 8:24AM $0.080 $0.059 fallen by 26.25%
$18 Noxopharm clinical trial submission 2 May 2025 8:45AM $0.077 $0.059 fallen by 23.38%
$18 March 2025 Quarterly Activities Report and Appendix 4C 30 Apr 2025 8:55AM $0.077 $0.059 fallen by 23.38%
$18 SOF-SKN successfully passes final pre-trial study 15 Apr 2025 8:22AM $0.069 $0.059 fallen by 14.49%
$18 Noxopharm expands collaboration with Hudson Institute 25 Mar 2025 8:49AM $0.087 $0.059 fallen by 32.18%

51 - 75 of 800 results

Page 3 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.